Physician profile
Max Feldman
NPI 1740556091
$1,639.87
in general payments reported to CMS, 2019-2025
21 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.06 · 2021: $67.98 · 2022: $410 · 2023: $432 · 2024: $310 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,147.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $537.60 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $189.70 | 2021-2025 | |
| Abbvie INC. | $133.99 | 2023-2025 | |
| Glaxosmithkline, LLC. | $129.48 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $73.17 | 2023 | Quviviq |
| Corium, LLC | $66.69 | 2023-2025 | Azstarys |
| Astrazeneca Pharmaceuticals Lp | $64.69 | 2023-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $62.34 | 2022-2025 | Mounjaro, Zepbound |
| Dynavax Technologies Corporation | $53.20 | 2024-2025 | Heplisav-B |
| Amgen INC. | $51.43 | 2024-2025 | Repatha, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $42.09 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $38.67 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $32.99 | 2022-2023 | |
| Exact Sciences Corporation | $32.59 | 2023 | Cologuard Collection Kit |
| Phadia US INC. | $26.52 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $20.16 | 2025 | Jornay Pm |
| Alk-Abello, INC | $19.20 | 2025 | Neffy, Grastek, Odactra |
| Lucid Diagnostics INC. | $17.89 | 2023 | |
| Globus Medical, INC. | $17.08 | 2025 | Senza |
| Ultragenyx Pharmaceutical INC. | $16.33 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.